ERBB2 and breast cancer: 111In-DTPA-NLS-trastuzumab exhibited high tumour uptake (12.1%ID/g) at 72 h p.i. in mice with HER2-overexpressing MDA-MB-361 human breast cancer xenografts (Costantini et al. 2007).